Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.74 |
| ▸ | CTSC | P53634 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | BLK | P51451 | 1/20 | 0.59 |
| ▸ | BMX | P51813 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 5/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706135 | 0.85 | EGFR (0.72) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL1707115 | 0.81 | EGFR (0.83) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL2949686 | 0.78 | BRD4 (0.63) | EGFRJAK2FLT3BRD4ALK | |
| SCHEMBL16370940 | 0.78 | EGFR (0.71) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL10127917 | 0.78 | CTSC (0.71) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL1706808 | 0.77 | EGFR (1.00) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL23704663 | 0.75 | ALK (0.74) | EGFRCTSCJAK2JAK3MAP2K1 | |
| SCHEMBL30331219 | 0.75 | ALK (0.74) | EGFRCTSCJAK2JAK3MAP2K1 | |
| SCHEMBL29351880 | 0.74 | EGFR (1.00) | EGFRCTSCJAK2BLKBMX | |
| SCHEMBL30854720 | 0.74 | EGFR (1.00) | EGFRCTSCJAK2BLKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2440559-B1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885CTSC 1415/4885JAK2 14/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | EGFR 1/4885CTSC 1415/4885JAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.